At approximately $120-150 per month, it is significantly less expensive than tirzepatide while offering comparable efficacy at higher doses
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Altimmunes GLP-1 agonist in the clinic Some biotechs think that by broadening the therapeutic scope of GLP-1 agonists, cardiovascular diseases can be addressed
Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain
Huang C, Dong L, Zhao B, Lu Y, Huang S, Yuan Z